Panorama of artery endothelial cell dysfunction in pulmonary arterial hypertension

J Mol Cell Cardiol. 2024 Dec:197:61-77. doi: 10.1016/j.yjmcc.2024.10.004. Epub 2024 Oct 20.

Abstract

Pulmonary arterial hypertension (PAH) is a fatal lung disease characterized by progressive pulmonary vascular remodeling. The initial cause of pulmonary vascular remodeling is the dysfunction of pulmonary arterial endothelial cells (PAECs), manifested by changes in the categorization of cell subtypes, endothelial programmed cell death, such as apoptosis, necroptosis, pyroptosis, ferroptosis, et al., overproliferation, senescence, metabolic reprogramming, endothelial-to-mesenchymal transition, mechanosensitivity, and regulation ability of peripheral cells. Therefore, it is essential to explore the mechanism of endothelial dysfunction in the context of PAH. This review aims to provide a comprehensive understanding of the molecular mechanisms underlying endothelial dysfunction in PAH. We highlight the developmental process of PAECs and changes in PAH and summarise the latest classification of endothelial dysfunction. Our review could offer valuable insights into potential novel EC-specific targets for preventing and treating PAH.

Keywords: Endothelial cells; Endothelial dysfunction; Pulmonary hypertension; Pulmonary vascular remodeling.

Publication types

  • Review

MeSH terms

  • Animals
  • Apoptosis
  • Endothelial Cells* / metabolism
  • Endothelial Cells* / pathology
  • Humans
  • Hypertension, Pulmonary / metabolism
  • Hypertension, Pulmonary / pathology
  • Hypertension, Pulmonary / physiopathology
  • Pulmonary Arterial Hypertension* / metabolism
  • Pulmonary Arterial Hypertension* / pathology
  • Pulmonary Arterial Hypertension* / physiopathology
  • Pulmonary Artery* / metabolism
  • Pulmonary Artery* / pathology
  • Vascular Remodeling